Literature DB >> 10657912

The international system for staging lung cancer.

C F Mountain1.   

Abstract

The International System for Staging Lung Cancer is a consistent, reproducible classification for the anatomic extent of disease in patients with lung cancer. A revision of the system in use since 1986 included modifications of the rules for stage grouping the TNM (T-primary tumor, N-regional lymph nodes, and M-distant metastasis) anatomic subsets. More specific stage categories and consistency for reporting the end results for Stage I, Stage II, and Stage IIIA disease are provided. Survival data support the revised categories and confirm the significant relationship between the extent of the disease and prognosis for patients with this disease. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10657912     DOI: 10.1002/(sici)1098-2388(200003)18:2<106::aid-ssu4>3.0.co;2-p

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  49 in total

Review 1.  Adjuvant therapy for resected non-small-cell lung cancer: recent advances, emerging agents, and lingering questions.

Authors:  Tara L Lin; Julie R Brahmer
Journal:  Curr Oncol Rep       Date:  2004-07       Impact factor: 5.075

Review 2.  Adjuvant therapy for resected non-small-cell lung cancer: past, present, and future.

Authors:  Rosalyn A Juergens; Julie R Brahmer
Journal:  Curr Oncol Rep       Date:  2005-07       Impact factor: 5.075

3.  Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air-liquid interface method.

Authors:  Seung-Wook Kim; Kyounga Cheon; Chang-Hoon Kim; Joo-Heon Yoon; David H Hawke; Ryuji Kobayashi; Ludmila Prudkin; Ignacio I Wistuba; Reuben Lotan; Waun Ki Hong; Ja Seok Koo
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

Review 4.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

5.  Moving forward with circulating tumor cells and lung cancer.

Authors:  T Jeroen N Hiltermann; Anthonie J van der Wekken; Harry J M Groen
Journal:  J Thorac Dis       Date:  2012-10       Impact factor: 2.895

6.  Occult lung infarction may induce false interpretation of 18F-FDG PET in primary staging of pulmonary malignancies.

Authors:  Ehab M Kamel; Thomas A McKee; Maria-Lucia Calcagni; Sabine Schmidt; Serge Markl; Sandra Castaldo; Angelika Bischof Delaloye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02-22       Impact factor: 9.236

7.  Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma.

Authors:  Stephen P Malkoski; Sarah M Haeger; Timothy G Cleaver; Karen J Rodriguez; Howard Li; Shi-Long Lu; William J Feser; Anna E Barón; Daniel Merrick; Jessyka G Lighthall; Hideaki Ijichi; Wilbur Franklin; Xiao-Jing Wang
Journal:  Clin Cancer Res       Date:  2012-03-07       Impact factor: 12.531

8.  Development of a rabbit pleural cancer model by using VX2 tumors.

Authors:  Kelly A Kreuter; Naglaa El-Abbadi; Alia Shbeeb; Lillian Tseng; Sari Brenner Mahon; Navneet Narula; Tanya Burney; Henri Colt; Matthew Brenner
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

9.  Positron emission tomography in the management of lung cancer.

Authors:  Vahid Reza Dabbagh Kakhki
Journal:  Ann Thorac Med       Date:  2007-04       Impact factor: 2.219

10.  Gene Expression-Based Approaches in Differentiation of Metastases and Second Primary Tumour.

Authors:  Tõnu Vooder; Kristjan Välk; Raivo Kolde; Retlav Roosipuu; Jaak Vilo; Andres Metspalu
Journal:  Case Rep Oncol       Date:  2010-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.